Liquid Biopsy for Brain Cancer

Overseen By Katarzyna Jerzak, Dr

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Sunnybrook Health Sciences Centre

Must not be taking: Anticoagulants, Antiplatelets

Disqualifiers: Severe thrombocytopenia, Significant mass effect, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

60 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C).

Are You a Good Fit for This Trial?

Inclusion Criteria

I have a metastatic solid tumor, with or without brain or leptomeningeal spread.

Patients who were previously enrolled in the study and had negative CSF biomarkers may be re-enrolled at a later time point (e.g., upon progression of CNS disease).

I am eligible no matter when I started treatment for LMD.

Exclusion Criteria

Inability to understand or unwillingness to provide written informed consent (language barriers are not exclusionary; the use of a translator is permitted).

I do not have any conditions that make a lumbar puncture unsafe for me.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Participants undergo a one-time CSF collection via lumbar puncture or Ommaya reservoir, with concurrent collection of peripheral blood for plasma-based liquid biopsy

1 day

1 visit (in-person)

Analysis

Analysis of CSF and blood samples for biomarkers, including cytology, ctDNA, and CTCs, and comparison with plasma results

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after sample collection and analysis

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• CSF and Blood Plasma Liquid Biopsy

How Is the Trial Designed?

Group I: CSF and Blood collection Experimental Treatment 1 Intervention

All the patients will perform the same intervention (One-time CSF and blood sample)

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials

693

Recruited

1,569,000+